Roivant Sciences Ltd. (ROIV) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 London, 영국. 현재 CEO는 Matthew Gline.
ROIV 을(를) 보유 IPO 날짜 2020-12-08, 908 명의 정규직 직원, 에 상장 NASDAQ Global Market, 시가총액 $20.84B.
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company headquartered in London that researches and develops innovative medicines across multiple therapeutic areas. The company's pipeline includes product candidates targeting oncologic malignancies, rare genetic disorders such as sickle cell disease and hypophosphatasia, and various inflammatory and dermatological conditions including psoriasis, atopic dermatitis, and vitiligo. Additional focus areas encompass autoimmune diseases, ophthalmologic disorders, and infectious diseases. Founded in 2014, Roivant combines drug development expertise with healthcare technology capabilities to address significant unmet medical needs globally.
